GSK, Inventor Urge Fed. Circ. To Review Tafas V. Doll

By Erin Coe

Law360, New York (June 04, 2009, 12:00 AM ET) -- A federal appeals court’s decision that upheld most of the U.S. Patent and Trademark Office’s rules putting new restrictions on patent applicants improperly expands the agency’s authority and threatens to stifle innovation, according to two petitions calling for a review of the controversial Tafas v. Doll ruling.

Pharmaceutical firm GlaxoSmithKline PLC and inventor Triantafyllos Tafas filed petitions in the U.S. Court of Appeals for the Federal Circuit on Wednesday seeking a rehearing or rehearing en banc of the March 20 decision that sided for the most...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

Already a subscriber?

  2. Forgot your password?
  4. Sign In

Get instant access to the one-stop news source for business lawyers

You must correct or enter the following before you can submit this form:

Required

Register